摩根大通发表研究报告指,康方生物(09926.HK) 上半年业绩表现低于预期,主要是利润率下降和营运支出高于预期,该行相信,最值得留意是集团宣布HARMONi-A在最终分析达到总生存期(overall survival)的统计显著性,这突显ivonescimab的差异化优势及其成为下一代关键免疫疗法之一的潜力。该行指,在12种药物的第三期或注册临床试验正进行中,未来几年其可持续发展将面临许多潜在...
Source Link摩根大通发表研究报告指,康方生物(09926.HK) 上半年业绩表现低于预期,主要是利润率下降和营运支出高于预期,该行相信,最值得留意是集团宣布HARMONi-A在最终分析达到总生存期(overall survival)的统计显著性,这突显ivonescimab的差异化优势及其成为下一代关键免疫疗法之一的潜力。该行指,在12种药物的第三期或注册临床试验正进行中,未来几年其可持续发展将面临许多潜在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.